Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of MVA-BN-RSV vaccine in adults aged 60 years and older
2021-004923-34Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing MVA-BN-RSV vaccine with Placebo (2 arms). Primary endpoint: Occurrence of RSV-associated lower respiratory tract disease. Started Feb 2022; status: completed.
02
Drugs
MVA-BN-RSV
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-004923-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004923-34.